drug
(alogliptin benzoate + pioglitazone hydrochloride)
Marketedupdated 4mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 27, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Jun 4, 2029formulationUS 86370792.7y
- Jun 4, 2029formulationUS 86370792.7y
- Jun 4, 2029formulationUS 86370792.7y
- Jun 4, 2029formulationUS 86370792.7y
- Jun 4, 2029formulationUS 86370792.7y
- Jun 4, 2029formulationUS 86370792.7y
- Jun 27, 2028compositionUS 78076891.8y
- Jun 27, 2028compositionUS 78076891.8y
- Jun 27, 2028compositionUS 78076891.8y
- Jun 27, 2028compositionUS 78076891.8y
- Jun 27, 2028compositionUS 78076891.8y
- Jun 27, 2028compositionUS 78076891.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that